A shares: Ganfeng lithium and other seven companies important announcement

2022-04-25 0 By

1. Ganfeng Lithium:Announcement of Ganfeng Lithium. Recently, the company and its wholly-owned subsidiary Ganfeng International signed a Cooperation Agreement with PMI, which agreed that PMI would provide the spodumene sold exclusively in Mt Marion Spodumene project to the company, and the company would process it into lithium compound products agreed by both parties.And the company is responsible for sales.Up to now, the company and PMI each hold 50% stake in RIM Australia. RIM’s Mt Marion spodumene project is one of the largest spodumene producers in the world.Recently, the company informed of the RIM, RIM’s management is considering minerals through the production process optimization and development contact way to Mt Marion spodumene project technical capacity of expansion, the expansion project is expected in the second half of 2022 and put into production, will be increased by 10-15% of origin are expected to scale, in addition to the new contact minerals capacity,An additional 10-15% capacity increase is expected, depending on process optimization results and the actual conditions of the contact ore.2. Yuanlong Yatu: A number of shareholders plan to reduce their total holdings by no more than 0.315%. Yuanlong Yatu announced that some directors, supervisors and senior managers plan to reduce their holdings by no more than 0.315%.Controlling shareholders reduced their holdings of 109,387 shares of the company in a block transaction on February 8.3, Zhifei biological performance letters: 2021 net profit increased 209% year on year. Zhifei biological performance letters, 2021 net profit of 10.197 billion yuan, a year-on-year increase of 208.88%.4. Watson Biological: the subsidiary received the announcement of Watson Biological on the ethical approval for overseas clinical trial of recombinant Novel Coronavirus variant vaccine (CHO cell). The subsidiary received the ethical approval for overseas clinical trial of recombinant Novel Coronavirus variant vaccine (CHO cell) and obtained CEPI funding.5. Shengxiang Creatures:Shengxiang Biological announced that the company completed the buyback and has actually repurchased 4,791,299 shares of the company, accounting for 1.2% of the company’s total share capital of 400 million shares. The highest buyback price is 69.2 yuan/share, the lowest buyback price is 49.97 yuan/share, and the average buyback price is about 54.29 yuan/share.The total amount of funds used is about 260 million yuan.Taihe Technology announced that the company plans to use its own funds 204.5 million yuan to invest in the construction of an annual output of 20,000 tons of VC(vinyl carbonate) project, the project is divided into two phases, the first phase and the second phase respectively to build an annual output of 10,000 tons of VC(vinyl carbonate) project.Vanke A announced that in January 2022, the company realized the contract sales area of 2.106 million square meters and the contract sales amount of 35.60 billion yuan.